These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 25361407)

  • 21. Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design.
    Williams PL; Hazra R; Van Dyke RB; Yildirim C; Crain MJ; Seage GR; Civitello L; Ellis A; Butler L; Rich K;
    AIDS; 2016 Jan; 30(1):133-44. PubMed ID: 26731758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
    Gibb DM; Kizito H; Russell EC; Chidziva E; Zalwango E; Nalumenya R; Spyer M; Tumukunde D; Nathoo K; Munderi P; Kyomugisha H; Hakim J; Grosskurth H; Gilks CF; Walker AS; Musoke P;
    PLoS Med; 2012; 9(5):e1001217. PubMed ID: 22615543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In utero exposure to HIV and/or antiretroviral therapy: a systematic review of preclinical and clinical evidence of cognitive outcomes.
    McHenry MS; Balogun KA; McDonald BC; Vreeman RC; Whipple EC; Serghides L
    J Int AIDS Soc; 2019 Apr; 22(4):e25275. PubMed ID: 30983111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exposure to antiretroviral agents during pregnancy does not alter bone status in infants.
    Mora S; Giacomet V; Viganò A; Cafarelli L; Stucchi S; Pivetti V; Manfredini V; Puzzovio M; Zuccotti G
    Bone; 2012 Jan; 50(1):255-8. PubMed ID: 22080170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of in-utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected.
    Crowell CS; Williams PL; Yildirim C; Van Dyke RB; Smith R; Chadwick EG; Seage GR; Diperna A; Hazra R;
    AIDS; 2020 Jul; 34(9):1377-1387. PubMed ID: 32310900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in Neonatal Prophylaxis and Predictors of Combination Antiretroviral Prophylaxis in US Infants from 1990 to 2015.
    Williams PL; Huo Y; Rutstein R; Hazra R; Rough K; Van Dyke RB; Chadwick EG
    AIDS Patient Care STDS; 2018 Feb; 32(2):48-57. PubMed ID: 30346801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of health programmes to prevent vertical transmission of HIV. Advances, emerging health challenges and research priorities for children exposed to or living with HIV: Perspectives from South Africa.
    Goga A; Slogrove A; Wedderburn CJ; Feucht U; Wessels J; Ramokolo V; Bhana A; Du Plessis N; Green RJ; Pillay Y; Sherman G
    S Afr Med J; 2019 Dec; 109(11b):77-82. PubMed ID: 32252873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In utero antiretroviral exposure and sociodemographic characteristics on neurodevelopment of HIV-exposed uninfected children versus HIV-unexposed uninfected healthy children in Malawi.
    Zhang X; Wang L; Han J; Xie L; Wu N; Nyirenda R; Shumba K; Simwanza W; Kulyk O; Chilapondwa V; Li X
    Int J Gynaecol Obstet; 2021 Jun; 153(3):424-437. PubMed ID: 33270235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lower birth weight-for-age and length-for-age z-scores in infants with in-utero HIV and ART exposure: a prospective study in Cape Town, South Africa.
    Nyemba DC; Kalk E; Madlala HP; Malaba TR; Slogrove AL; Davies MA; Boulle A; Myer L; Powis KM
    BMC Pregnancy Childbirth; 2021 May; 21(1):354. PubMed ID: 33947351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in Growth of HIV-exposed Uninfected Infants in Ethiopia According to Timing of In-utero Antiretroviral Therapy Exposure.
    Ejigu Y; Magnus JH; Sundby J; Magnus MC
    Pediatr Infect Dis J; 2020 Aug; 39(8):730-736. PubMed ID: 32516280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurodevelopmental outcomes and in-utero antiretroviral exposure in HIV-exposed uninfected children.
    Piske M; Budd MA; Qiu AQ; Maan EJ; Sauvé LJ; Forbes JC; Alimenti A; Janssen P; Côté HCF;
    AIDS; 2018 Nov; 32(17):2583-2592. PubMed ID: 30134292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-utero exposure to antiretrovirals and neurodevelopment among HIV-exposed-uninfected children in Botswana.
    Chaudhury S; Mayondi GK; Williams PL; Leidner J; Shapiro R; Diseko M; Ajibola G; Holding P; Tepper V; Makhema J; Petlo C; Seage GR; Lockman S; Kammerer B
    AIDS; 2018 Jun; 32(9):1173-1183. PubMed ID: 29547434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of antenatal antiretroviral drug exposure on the growth of children who are HIV-exposed uninfected: the national South African Prevention of Mother to Child Evaluation cohort study.
    Ramokolo V; Kuhn L; Lombard C; Jackson D; Goga AE
    BMC Infect Dis; 2022 Dec; 22(1):908. PubMed ID: 36474212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurologic Outcomes in HIV-Exposed/Uninfected Infants Exposed to Antiretroviral Drugs During Pregnancy in Latin America and the Caribbean.
    Spaulding AB; Yu Q; Civitello L; Mussi-Pinhata MM; Pinto J; Gomes IM; Alarcón JO; Siberry GK; Harris DR; Hazra R
    AIDS Res Hum Retroviruses; 2016 Apr; 32(4):349-56. PubMed ID: 26879281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): The Kesho Bora randomized controlled trial.
    Kesho Bora Study Group
    Clin Infect Dis; 2012 Aug; 55(3):449-60. PubMed ID: 22573845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?
    Thorne C; Newell ML
    Drug Saf; 2007; 30(3):203-13. PubMed ID: 17343429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated Blood Mitochondrial DNA in Early Life Among Uninfected Children Exposed to Human Immunodeficiency Virus and Combination Antiretroviral Therapy in utero.
    Ajaykumar A; Zhu M; Kakkar F; Brophy J; Bitnun A; Alimenti A; Soudeyns H; Saberi S; Albert AYK; Money DM; Côté HCF;
    J Infect Dis; 2021 Feb; 223(4):621-631. PubMed ID: 32638023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antenatal and neonatal antiretroviral therapy in HIV-infected women and their infants: a review of safety issues.
    Thorne C; Newell ML
    Med Wieku Rozwoj; 2003; 7(4 Pt 1):425-36. PubMed ID: 15010553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, pediatric spectrum of HIV disease cohort.
    Peters V; Liu KL; Dominguez K; Frederick T; Melville S; Hsu HW; Ortiz I; Rakusan T; Gill B; Thomas P
    Pediatrics; 2003 May; 111(5 Pt 2):1186-91. PubMed ID: 12728136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study.
    Pacheco SE; McIntosh K; Lu M; Mofenson LM; Diaz C; Foca M; Frederick M; Handelsman E; Hayani K; Shearer WT;
    J Infect Dis; 2006 Oct; 194(8):1089-97. PubMed ID: 16991083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.